Bullish indicating open at $55-$60, IPO prices at $37
Investing.com - Cantor Fitzgerald maintained its Overweight rating and $14.00 price target on Bioventus Inc (NASDAQ:BVS) following the company’s second quarter 2025 financial results. The stock, which has seen a notable 9.5% gain over the past week, currently trades below its InvestingPro Fair Value, suggesting potential upside opportunity.
Bioventus reported revenue of $147.7 million for the second quarter, exceeding both Cantor Fitzgerald’s estimate of $144.6 million and the FactSet consensus of $146.3 million. The reported revenue represents a year-over-year decline of 2.4%.
When excluding the impact from the prior-year divestiture of the Advanced Rehabilitation Business, Bioventus achieved 6.2% organic revenue growth compared to the same period last year. This growth was driven by double-digit organic increases across the company’s Surgical Solutions and Restorative Therapies segments.
The company generated approximately $26.0 million in cash flow from operations during the second quarter, a significant improvement from $11.0 million in the prior-year period. This increased cash generation is expected to support Bioventus in its efforts to reduce outstanding debt.
Bioventus has maintained its full-year 2025 guidance following these second quarter results, according to Cantor Fitzgerald’s report.
In other recent news, Bioventus Inc. reported its earnings for the second quarter of 2025, with earnings per share (EPS) of $0.21, meeting market forecasts. The company’s revenue slightly exceeded expectations, reaching $147.7 million compared to the forecast of $146.28 million. These results highlight Bioventus’s ability to align closely with analyst projections while achieving a modest revenue beat. The announcement of these financial results was followed by an increase in the company’s stock price, although specific stock movements are not detailed here. These developments come amid a broader context of ongoing market analysis and investor interest. The financial performance of Bioventus is being closely monitored by analysts and investors alike. As the company continues to release its quarterly results, these figures are crucial for understanding its current market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.